Latest tools for COVID-19 Omicron variant research

AMSBIO has announced new additions to its portfolio of tools for COVID-19 research – two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.